Banks (AABB) surveyed 2250 Institutional Members by questionnaire. Facilities surveyed were of three types as defined by the 1989-1990 AABB Membership Directory: (A) blood centers, non-hospital-based facilities that collect blood from at least 100 donors per year and primarily supply blood and components to other facilities; (B) hospital blood banks, which collect blood from at least 100 donors per year and transfuse patients; and (C) transfusion services, which collect blood from less than 100 donors per year and supply at least 100 units per year for transfusion (includes those not meeting requirements for blood centers or hospital blood banks).
Institutions were first asked whether they had facilities for irradiation of blood components. If they had irradiation facilities, they were asked to specify the type of irradiator used and whether they irradiate blood components for other facilities. If they did not have irradiation facilities, they were asked whether their blood components were irradiated at a blood center or hospital. Secondly, institutions were asked to provide the total number of blood components transfused and the total number of blood components irradiated in 1989. In addition, they were asked whether it was their policy to irradiate cellular and/or acellular products. The third set of questions addressed the dose of irradiation used and asked whether irradiated blood components were provided to the following patient groups: congenital immunodeficiency syndromes, premature newborns, term newborns, recipients of autologous BMT, recipients of allogeneic BMT, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, solid tumors, recipients of HLA-matched products, acquired immunodeficiency syndrome (AIDS), and recipients of organ transplants. With regard to directed donations, institutions were asked whether they provided irradiated donations from (1) all family members; (2) first degree (parent + child; sibling e sibling) relatives; and (3) nonblood relatives.
Finally, institutions were asked whether they had ever documented any cases of TA-GVHD and, if so, to specify the number of cases and patients' diagnoses.
One-thousand four hundred forty-four of 2,250 (64.2%) questionnaires were returned and analyzed: 99 from blood centers, 397 from hospital blood banks, and 948 from transfusion services. One-thousand two hundred sixty-six (87.7%) do not have on-site facilities for gamma irradiation; 178 (12.3%) of the institutions have on site facilities for the irradiation of blood components, including 21 of 99 (21.2%) blood centers, 76 of 397 (19.1%) hospital blood banks, and 81 of 948 (8.5%) transfusion services. Eighty-seven of 166 (52.4%) institutions also irradiate for other facilities, blood centers more commonly (78.9%) than either hospital blood banks (49%) or transfusion services (50% (Fig 1) . Only 1 (0.02%) institution used doses less than 15
The patient groups who receive irradiated blood components are shown in Table 1 . A large number of responding institutions (26.4% to 58.4%) answered "nonapplicable"; analyses were therefore performed after excluding these "nonapplicable" respondents to more accurately define irradiation practices for each patient subgroup (Fig 2) . A majority of institutions provide irradiated components for recipients of allogeneic BMT (88%), recipients of autologous BMT (81.4%), and for patients with congenital immunodeficiency syndromes (68.4%). Although 53.9% of institutions irradiate blood products for premature newborns, only 24% of institutions provide irradiated components to term newborns. Institutions were evenly split as to whether they provided irradiated blood products to patients with leukemias (51.4%) or did not do so (48.6%). Organ transplant recipients, patients with Hodgkin's disease, and those with non-Hodgkin's lymphomas receive irradiated components at 40.4%, 34%, and 32% of institutions, respectively. Recipients of HLAmatched products receive irradiated blood components at 31% of responding institutions. Finally, patients with AIDS and solid tumors receive irradiated blood components at a minority (24.5% and 20%, respectively) of centers.
Type and amount of irradiated blood components used.
GY.
Patient groups at risk for TA-GVHD.
Institutions were then surveyed as to whether they irradiated directed donors from all family members, first degree family members, and from nonblood relatives. Although a minority (31.6%) of institutions irradiated directed donations from all family members, a majority (88.9%) of institutions irradiate directed donations from first degree family members (Table 2 ). In contrast, the overwhelming majority (90%) of institutions do not irradiate directed donations from nonblood relatives.
Fortytwo of 1,327 (3.2%) institutions have documented cases of TA-GVHD (Table 3 ). It has most commonly been noted in patients with Hodgkin's disease (11 cases) and after allogeneic BMT (12 cases); in two of the 12 cases of GVHD after BMT, it was specifically stated that patients had received only irradiated blood products.
Documented and suspected cases of TA-GVHD.
RISK GROUPS FOR TRANSFUSION ASSOCIATED GVHD
Risks well defined. It is reasonable at this time to propose guidelines for identification of those at risk for TA-GVHD (Table 4 ) and for the irradiation of blood products in transfusion medicine practice based on the current survey, coupled with a review of reported experience of TA-GVHD. In 1986, the National Institutes of Health Consensus Development Conference defined patients who have undergone BMT or those with other forms of immunodeficiency as candidates for irradiated platelet concentrates to avoid GVHD.62 However, our survey indicates that 31.6% of institutions do not irradiate cellular components transfused to patients with congenital immune deficiency syndromes; moreover, 12% and 18.6% of institutions do not provide irradiated products for recipients of allogeneic and autologous BMT, respectively. This finding is surprising because there would appear to be little controversy that these patients have profound congenital or acquired immune dysfunction that predisposes them to GVHD. They should therefore uniformly receive only irradiated blood components. Intrauterine transfusions are also well documented as a cause of TA-GVHD,'6-'8 and only irradiated components should also be used in this setting. Risks under review. Although TA-GVHD has been reported in the setting of hemolytic disease of the newborn and in premature or newborn infant^,'^." there remains disagreement about its incidence and whether preventative methods are necessary. Cases are described in premature newborn^,'^-'^^'^ and approximately 50% of institutions surveyed provide irradiated transfusions to these patients. Thus, delineation of the risks of TA-GVHD in this group require further study. Term newborns, in contrast, uncommonly develop TA-GVHD'8z2"; yet 25% of survey institutions irradiate cellular components for these patients. The rarity of reports in the literature and our survey suggests that routine irradiation practices are not warranted at this time.
Patients with hematologic malignancies and solid tumors may be immunosuppressed either secondary to chemotherapy and/or radiation therapy or due to intrinsic immune dysfunction (eg, Hodgkin's disease). A number of cases of TA-GVHD have been noted in patients with Hodgkin's disease2'"' and are reported in our survey. These cases include not only patients receiving combined chemotherapy and radiation therapy, but also patients receiving chemotherapy only, supporting the view that all patients with Hodgkin's disease should receive irradiated blood components. Patients with other hematologic malignancies have been reported to develop TA-GVHD,3''49 and 32% and 51.4% of institutions surveyed irradiate blood components for patients with non-Hodgkin's lymphoma and leukemia, respec- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From tively. In addition, patients with solid tumors have developed TA-GVHD,50-54 usually in the setting of high-dose chemotherapy. However, at present irradiation cannot be routinely recommended for all patients with either hematologic malignancies or tumors of solid organs.
There have been no reported cases of TA-GVHD in patients with AIDS, and none were documented in our survey. Because profound in vitro immunodeficiency is demonstrable in these patients,63 they would appear to be at risk for TA-GVHD. Perhaps TA-GVHD is underrecognized and some of the signs and symptoms (rashes, pancytopenia, liver function abnormalities) presently attributed to infections, drug reactions, and other coexistent medical conditions in patients with AIDS may be related to TA-GVHD. Alternatively, HIV infection of transfused donor lymphocytes may abrogate the development of TA-GVHD. The absence of TA-GVHD in patients with AIDS reinforces the fact that the degree and type of immunosuppression that may predispose a patient to TA-GVHD remain undefined.
Transfusions from donors homozygous for an HLA haplotype to a recipient sharing this haplotype may predispose to TA-GVHD in immunocompetent patient^."-^' Indeed, the specialized set-
No risks defined.
Risks in immunocompetent hosts. ting recently reported from Israel involved a donor who was homozygous for a recipient HLA hapl~type.'~ The homogeneity of the Israeli population and the likelihood of therefore having an extended haplotype-homozygous donor may explain the more frequent reports of TA-GVHD in these immunocompetent recipients. Homozygosity for HLA types is more likely to occur among first degree family members (ie, parents, children, and siblings); therefore, such relativeto-patient-directed donations may carry an increased risk of initiating TA-GVHD. Based on this potential predisposition for TA-GVHD, it has recently been recommended that cellular blood components prepared from such donors be irradiated with at least 15 Gy before transfusion.M Our survey does suggest that the majority (approximately 90%) of centers do irradiate donations from first degree blood relatives but not those from other family members or nonrelated donors. The lack of even greater uniformity in this policy may reflect the fact that our survey occurred before this recommendation could practically be implemented.
GUIDELINES FOR GAMMA IRRADIATION OF BLOOD COMPONENTS
The only currently proven effective method to prevent TA-GVHD is gamma irradiation of blood products before transfusion, a practice that has been in routine use by marrow transplant teams for more than two decade^.^' As little as 5 Gy of gamma irradiation can abrogate the response of lymphocytes to allogeneic cells in a mixed lymphocyte culture, and 15 Gy can reduce response to mitogen-induced stimulation by 90%.@z6' Moreover, Button et a1 examined the function of blood components after irradiation doses of 5 to 200 Gy and demonstrated that doses as high as 50 Gy decreased mitogen stimulation by 98.5%, but did not compromise function of cells other than lymphocytes.68 Specifically, irradiated red blood cells had the same survival as nonirradiated controls, granulocytes had normal in vitro bacterial killing capacity, chemotactic mobility, and superoxide production, and transfused irradiated platelets produced the expected increases in platelet counts and controlled hemostasis in thrombocytopenic patients. However, in this study doses of 50 Gy decreased the yield of platelets posttransfusion by one-third. Most recent studies suggest that irradiation at 15 to 20 Gy can For personal use only. on October 30, 2017. by guest www.bloodjournal.org From reduce mitogen-responsive lymphocytes by 5 to 6 logs compared with unirradiated controls.69 These and other studies of the effects of gamma irradiation on in vitro cell function and posttransfusion recovery support the recommendation that the lowest dose capable of inhibiting lymphocyte proliferation (15 to 25 Gy) be used to irradiate blood components before transfusion." From our survey, 96.8% of institutions used doses of 15 to 35 Gy. However, it should be emphasized that a small percentage of lymphocytes survive irradiation at these doses. Moreover, a single reported case of apparent transfusion related GVHD in a BMT recipient who received only blood components irradiated at 20 Gy,@ along with two similar cases detected in our survey, suggest that existing blood product irradiation guidelines may require reassessment.
Several studies have addressed the potential adverse consequences of irradiation, ie, release of potassium into irradiated blood. The extent of potassium release may require that irradiated red cells for intrauterine, neonatal, or pediatric transfusions be washed to reduce potassium levels.71 This issue remains controversial because others have suggested that the total infusion load of potassium is so low that it is not clinically ~ignificant.~' Studies to date do suggest no adverse effects of irradiation on storage of platelet^,^^,^^ but further studies are necessary to assess the effect of irradiation and storage on red cells and its implications for a regional approach to irradiation of blood components. It is also theoretically possible that radiation damage to transfused lymphocytes may cause adverse effects in recipients, but no evidence of such an outcome is documented at present.
The financial and logistical implications of blood product irradiation are great. Only 12% of surveyed institutions had facilities for irradiation. A Cesium-137 irradiator costs approximately $50,000, and there are additional costs for labor required to irradiate blood products. Clearly, not every transfusion service could absorb this cost. Because 88% of respondents do not have irradiators and their acquisition is expensive, a regional approach to this service seems prudent. If irradiation could be done at the time of blood product collection and before distribution to transfusion services without adverse effects on storage, then only one regional blood collection center would need to have irradiation facilities.
FUTURE DIRECTIONS
Potential alternative methods to prevent TA-GVHD include depletion of lymphocytes from blood products or ultraviolet irradiation of blood products before transfusion. It has been demonstrated in murine systems, as well as in humans, that T lymphocytes mediate GVHD and that the incidence and severity of GVHD postallogeneic BMT can be reduced if T cells are eliminated from the donor marrow before grafting by a variety of t e c h n i q~e s .~~.~~ While it may not be either possible or practical to treat blood components in a similar fashion, techniques are presently available that deplete 2 to 3 logs of l e~k o c y t e s ,~~,~~ so that leukopoor red cells and platelets would contain lo6 to lo8 lymphocytes. However, the number and precise T cells required to mediate TA-GVHD remain undefined, and it is therefore unknown whether depletion of leukocytes using these currently available techniques would decrease the risk of TA-GVHD. Finally, a canine model has been used to demonstrate that UV rather than gamma irradiation of transfused leukocytes can abrogate GVHD in recipient animals.79 Preliminary studies in humans have used UV irradiation of blood components to minimize alloimmunizatioqm but future studies are needed to determine whether UV light can avoid TA-GVHD in transfusion recipients without adverse effects on in vitro function or in vivo recovery of UV-treated red cells or platelets. 26. Schaerer R, Schaerer L, Sotto JJ: La reaction du greffon contre l'hote (GVHR) comme complication letale des transfusions de sang au cours de la maladie de Hodgkin: A propos de deux observations. Proc Premier Congres Francais d'Hematologie, Vittel, 1975 (abstr) 27. Groff P, Torhorst J, Speck B, Nissen C, Weber W, Cornu P, 
